From theheart.org on Medscape

Coverage from the

Heart Failure Association of the European Society of Cardiology (HFA-ESC) 2023

May 20 - 23, 2023; Prague, Czechia, and Online

May 20 - 23, 2023 Prague, Czechia, and Online

HFA-ESC 2023 ARNI Bests ARB to Reduce NT-proBNP in Stabilized HFpEF Sacubitril-valsartan led to a greater reduction of natriuretic peptides, less worsening renal function, but a higher rate of hypotension compared with valsartan in PARAGLIDE-HF.
Medscape Medical News, May 25, 2023
HFA-ESC 2023 Novel Antibody Safe, Promising for ATTR The recombinant human antibody NI006 was safe for the treatment of transthyretin amyloid cardiomyopathy in a small phase 1 trial and may also reduce amyloid protein accumulation in the heart.
Medscape Medical News, May 23, 2023

Conference News

HFA-ESC 2023 Big Boost in Sodium Excretion With HF Diuretic Protocol
Medscape Medical News, June 8, 2023
HFA-ESC 2023 EHR Nudges a Bust for Boosting GDMT in Acute HF: PROMPT-AHF
Medscape Medical News, June 6, 2023
HFA-ESC 2023 Dapagliflozin Matches Non-Loop Diuretic for AHF Congestion
Medscape Medical News, June 5, 2023
HFA-ESC 2023 ARNI Bests ARB to Reduce NT-proBNP in Stabilized HFpEF
Medscape Medical News, May 25, 2023

HFA-ESC 2023 Trientine Reduces NT-proBNP in HFrEF: TRACER-HF
Medscape Medical News, May 25, 2023
HFA-ESC 2023 Novel Antibody Safe, Promising for ATTR
Medscape Medical News, May 23, 2023
HFA-ESC 2023 CardioMEMS Boosts QoL, Curbs HF Hospitalizations: MONITOR-HF
Medscape Medical News, May 23, 2023

Popular News from HFA-ESC 2022

Voice-Analysis App Promising as Acute-HF Early Warning System It could potentially help guide heart failure therapy to avert acute decompensations, researchers say. 'But of course, we have to show that now in larger and randomized clinical studies.
Medscape Medical News, May 21, 2022
Moderate to High Alcohol Use May Push 'Pre-HF' Into Clinical HF Also, no protection was evident at any alcohol-intake level among STOP-HF trial participants who were initially at risk for heart failure but without echocardiographic signs of the disease.
Medscape Medical News, May 23, 2022
Dapagliflozin Early Benefit Explored in Reduced-EF Heart Failure Why have SGLT2-inhibitor clinical benefits in HFrEF trials been evident so soon after the drugs are started? Recent studies shed light on one potential mechanism among what are probably many.
Medscape Medical News, Jun 06, 2022

Previous Coverage

Related Resource

Heart Failure